Viewing Study NCT02169765



Ignite Creation Date: 2024-05-06 @ 2:55 AM
Last Modification Date: 2024-10-26 @ 11:26 AM
Study NCT ID: NCT02169765
Status: UNKNOWN
Last Update Posted: 2020-07-22
First Post: 2014-06-18

Brief Title: HR Versus RFA for Early Stage HCC
Sponsor: Guangxi Medical University
Organization: Guangxi Medical University

Study Overview

Official Title: Hepatic Resection Versus Radiofrequency Ablation for Early-stage Hepatocellular Carcinoma a Randomized Controlled Trial
Status: UNKNOWN
Status Verified Date: 2020-07
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ARTC-HCC
Brief Summary: Hepatocellular carcinoma HCC is the third leading death cancer in the world It is important to explore a safe and effective therapy for early-stage HCC Previous studies reported that radiofrequency ablation RFA has higher efficacy and is associated with fewer complications and shorter hospital stays than hepatic resection HR for early-stage HCC However meta-analysis and systematic review found that RFA is associated with higher recurrence rate and lower long-term overall survival
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
HRRFA-HCC REGISTRY Jian-Hong Zhong None